ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Model N Spring Release for Life Sciences: Continuous Innovation to Automate and Improve Front- and Back-Office Processes

Leader in Life Sciences Revenue Management Delivers Greater Pricing Accuracy and Timeliness for Increased Competitiveness, While Simplifying the Membership Management Process

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced its Life Sciences Spring 2021 release. The company’s latest update to its flagship product, Model N Revenue Cloud for Life Sciences, introduces numerous new capabilities and features that improve pricing accuracy and timeliness, help to drive additional business wins, increase competitiveness, and simplify the burden of aligning healthcare providers to their various GPO, IDN, and other hospital group affiliations.

Model N Revenue Cloud is a unified system of record for all revenue execution processes. The company’s ongoing product innovations deliver new end-to-end solutions that enable life sciences companies to intelligently automate and improve front- and back-office processes.

To make the buying and selling journey easier for customers, Model N’s latest release provides pharmaceutical and medtech manufacturers with new capabilities that help streamline the complex healthcare provider membership management process. This includes capabilities such as enhanced membership roster processing, smart data matching, and data transformation. In addition, enhancements to tiered pricing and regulatory compliance, Script data validation, and price and rebate management further assist life sciences companies in reducing revenue leakage caused by overpayments and incorrect pricing calculations.

Spring Release New Features

Purpose-built for pharma and medtech manufacturers, cloud-based Model N solutions support organizations throughout the entire revenue lifecycle – from initial product launch to product maturity and large-volume sales. Key new features of the Spring 2021 release supporting Model N’s end-to-end revenue vision include:

  • A new advanced membership management module, ensuring that correct pricing is provided to eligible customers at the right time through enhanced roster processing and smart address matching
  • Global pharmaceutical manufacturers can increase win rates with the integration of competitor product pricing from an industry-leading data provider to Global Pricing Management.
  • The Global Tender Management product is now integrated with various public tender marketplaces in Europe. This allows tender managers to search for newly published tenders and convert them to tender opportunities.
  • New insights into key financial data related to sales, rebates and revenue projections enable life sciences manufacturer’s sales organizations to streamline the customer business review process.

“This new release further demonstrates Model N’s commitment to innovation that focuses on intelligently automating and improving revenue management, pricing and compliance, while smartly addressing issues related to member management,” said Suresh Kannan, chief product officer at Model N. “Our focus on helping life sciences companies protect and improve their topline revenues has never been sharper. New features in the Spring 2021 release illustrate Model N’s ongoing commitment to innovation on behalf of its customers, so that they can reach their financial goals, no matter where they are in the revenue lifecycle journey.”

An Analyst Perspective

“The revenue, compliance and pricing needs of life science companies continues to evolve and face stiffer competition and pricing pressures, and solutions like Model N Revenue Cloud are critical to maintaining a competitive edge,” said Mike Townsend, research director, Life Sciences Commercial Strategies at IDC. “With this release, Model N consistently continues to innovate. The new capabilities for member management will clearly have an impact for its customers, and integrating competitive data into the pricing process will be a real differentiator for its customers.”

About Model N

Model N enables life sciences and high tech companies to drive growth and market share, minimizing revenue leakage throughout the revenue lifecycle. With deep industry expertise, solutions and business services purpose-built for these industries, Model N delivers comprehensive visibility, insight and control over the complexities of commercial operations and compliance. Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom and Microchip Technology. For more information, visit www.modeln.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.12
+0.94 (0.39%)
AAPL  255.53
-2.68 (-1.04%)
AMD  231.83
+3.91 (1.72%)
BAC  52.97
+0.38 (0.72%)
GOOG  330.34
-2.82 (-0.85%)
META  620.25
-0.55 (-0.09%)
MSFT  459.86
+3.20 (0.70%)
NVDA  186.23
-0.82 (-0.44%)
ORCL  191.09
+1.24 (0.65%)
TSLA  437.50
-1.07 (-0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.